BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Atomwise Inc.

Headquarters: San Francisco, CA, United States
Year Founded: 2012
Status: Private

BioCentury | Feb 20, 2025
Management Tracks

Bourla becomes chair of PhRMA

Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
BioCentury | Oct 3, 2023
Management Tracks

Affibody names Peter Zerhouni CFO

Plus: Restructuring at Kezar as CEO, CMO step down, and updates from Atomwise, Aura, Twist, Acelyrin and more
BioCentury | Sep 27, 2023
Deals

Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front

The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape 
BioCentury | Sep 25, 2023
Product Development

Instilling AI and scaling Dupixent: two pillars of Hudson’s strategy at Sanofi

A conversation with Sanofi CEO Paul Hudson 
BioCentury | Jul 31, 2023
Product Development

In Sanofi’s digital revolution, software product development is the common tongue

Everyone should understand how digital solutions to employee pain points get built, says Sanofi’s head of digital for R&D
BioCentury | Nov 9, 2022
Regulation

Nov. 8 Quick Takes: FDA request could extend review of BioMarin’s hemophilia therapy

Plus Sanofi’s latest AI deal taps Insilico and updates from Kronos, Marinus and more  
BioCentury | Sep 14, 2022
Management Tracks

AZ and Novartis veteran Tommasi to lead R&D at Dunad

Plus new CSOs at Atomwise and Sotio, and updates from Nine Square, Fabric and Biolojic Design
BioCentury | Feb 16, 2022
Discovery & Translation

Bridge Bio goes early with next-gen chemoproteomics

The Korean biotech’s collaboration with Vividion co-founders at Scripps will explore reactive chemistries beyond cysteine
BioCentury | Jan 26, 2022
Management Tracks

FDA’s Sipes leaving CDER for White House

Plus Ortiz joins Telix as COO, and updates from Chinook, Atomwise and more
BioCentury | Sep 22, 2021
Product Development

Unpartnered KRAS programs: Data Byte

Companies looking to in-license KRAS inhibitors may need to go early stage 
Items per page:
1 - 10 of 38